Treatment
Apatinib clinical trials
We’re tracking 84 recruiting studies that include Apatinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06447623RecruitingPhase 3
Apatinib plus CDK4/6 inhibitor for first-line HR+/HER2- SNF4 breast cancer
This trial tests a combination of two drugs, apatinib and a CDK4/6 inhibitor, as the first treatment for a specific type of advanced breast cancer that is HR+ and HER2-. It's designed for people with the 'SNF4' subtype, which is identified by a special analysis of your tumor sample.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07589244RecruitingPhase 2/Phase 3
VRT106 with Camrelizumab and Apatinib for Advanced Liver Cancer
This study tests a combination of three drugs—VRT106 (a new oncolytic virus therapy), camrelizumab (an immune-boosting drug), and apatinib (a targeted cancer drug)—to treat advanced hepatocellular carcinoma (HCC), a type of liver cancer. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT03736863RecruitingPhase 2
Testing combinations of medicines for advanced throat cancer
This trial tests a combination of medicines to treat advanced esophageal squamous cell carcinoma (throat/esophagus cancer) that cannot be removed by surgery and has spread or come back. It is for people whose first treatment (chemotherapy or immunotherapy) did not work well or was not tolerated.
Zhengzhou, HenanAges 18–75 - NCT04342910RecruitingPhase 3
Test camrelizumab plus apatinib for advanced stomach cancer
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
BeijingAges 18 years+ - NCT04501705Recruiting
Apatinib for adults with recurring atypical or malignant meningioma
This trial tests whether apatinib can shrink or control recurring atypical/malignant meningioma that has come back after surgery and radiation. It focuses on adults with measurable regrowth on MRI and good overall health to safely take an oral medicine.
Beijing, Beijing MunicipalityAges 18–70 - NCT04501718RecruitingPhase 2
Study of apatinib plus chemotherapy for recurrent childhood medulloblastoma
This trial tests whether adding apatinib to temozolomide and etoposide helps children whose medulloblastoma has come back. It aims to slow the tumor and improve outcomes after standard treatments.
BeijingAges 2–21 - NCT05027386RecruitingPhase 1/Phase 2
Apatinib plus immunotherapy for tough childhood neuroblastoma
This trial studies whether apatinib, a targeted medicine, combined with an immunotherapy treatment can shrink or control neuroblastoma that has come back or does not respond to prior treatment. Because it is a Phase I/II single-group study, everyone receives the planned treatment and researchers watch side effects and response.
Guangzhou, GuangdongAges 5–18 - NCT05412589RecruitingPhase 2
Testing three cancer medicines for advanced liver cancer
This trial studies how well a combination of chemotherapy, immunotherapy, and an anti-angiogenesis medicine works for advanced hepatocellular carcinoma (HCC), a type of liver cancer. It may help slow tumor growth and improve outcomes by attacking cancer in different ways.
Guangzhou, GuangdongAges 18–75 - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT05512481RecruitingPhase 2
Study combination treatment before surgery for high-risk acral melanoma
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
Beijing, Beijing MunicipalityAges 18–75 - NCT05613478RecruitingPhase 3
Immunotherapy plus targeted medicine with TACE around liver surgery
This Phase 3 trial tests whether combining camrelizumab and apatinib with TACE before/around liver cancer surgery can improve outcomes for people with certain stages of hepatocellular carcinoma (HCC). It may help by strengthening the immune attack on cancer and by blocking blood supply to tumors.
Nanjing, JiangsuAges 18 years+ - NCT05751733Recruiting
Apatinib versus standard drug for advanced GIST after imatinib
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
Changsha, HunanAges 18 years+ - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT06099821RecruitingPhase 2
KN046 plus targeted pills for resistant MSI-H digestive cancers
This trial tests two types of targeted therapy pills (Regorafenib or Apatinib) combined with a new immunotherapy drug (KN046). It is for people with MSI-H or dMMR digestive system cancers that have stopped responding to standard immunotherapy.
BeijingAges 18 years+ - NCT06296563RecruitingPhase 2
Testing adebrelimab, apatinib, and HAIC for bile duct cancer
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
Jinan, ShandongAges 18 years+ - NCT06339619RecruitingPhase 2
Combination immunotherapy for advanced esophageal cancer after prior treatment
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Guangzhou, GuangdongAges 18–75 - NCT06349317RecruitingPhase 2
Radiation, immunotherapy, and targeted therapy before surgery for liver cancer with portal vein tumor thrombus
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
Fuzhou, FujianAges 18–75 - NCT06415669RecruitingPhase 2
Combination therapy for advanced stomach cancer after immunotherapy
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
Fuzhou, FujianAges 18–75 - NCT06438627RecruitingPhase 3
New triple therapy vs standard for advanced nasopharyngeal cancer
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
Guangzhou, GuangdongAges 18–65 - NCT06454578RecruitingPhase 2
Study of adebrelimab plus apatinib after liver cancer surgery
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Jinan, ShandongAges 18 years+ - NCT06480864Recruiting
Study of adebelimumab and apatinib for extensive stage small cell lung cancer maintenance
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Shenyang, LiaoningAges 18 years+ - NCT06576973RecruitingPhase 2
Adalimumab combo therapy for esophageal cancer before surgery
This trial tests a combination of an immunotherapy drug (adalimumab), chemotherapy, and a targeted therapy pill (apatinib) before surgery for esophageal cancer that can be removed. The goal is to see if this mix helps shrink the tumor and improve outcomes.
Hangzhou, ChinaAges 18–75 - NCT06607770RecruitingPhase 1/Phase 2
Cryoablation with immunotherapy for multiple lung cancers
This trial tests freezing tumors (cryoablation) combined with two drugs (Karelizumab and Apatinib) for people who have several small lung cancer spots in their lungs but no spread to lymph nodes. The goal is to see if this combination is safe and helps shrink or control the tumors.
Guangzhou, GuangdongAges 18–75 - NCT06749691RecruitingPhase 2
Liposomal irinotecan and apatinib for extensive-stage small cell lung cancer
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75
Common questions
- Are there clinical trials studying Apatinib?
- Yes. Clin2 currently lists 84 recruiting studies that include Apatinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Apatinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Apatinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Apatinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.